Kashiv BioSciences, LLC is a fully integrated biosciences company headquartered in Bridgewater, New Jersey with locations in Piscataway, NJ, Chicago IL, and Ahmedabad, India. Kashiv BioSciences’ broad business offering includes drug delivery platforms incorporating delayed release technology and gastric retention systems that improve the efficacy and safety of known drugs, a 505(b)(2) pipeline of development products targeting unmet clinical needs, biosimilars and prodrugs. Additionally, as part of a development collaboration Kashiv BioSciences has approved generic products and products in advanced stages of development, including several complex generic products. Kashiv BioSciences’ medications will improve the lives of patients suffering from cancer as well as neuromuscular, movement and endocrine disorders, among other debilitating conditions, both in the U.S. and globally. The combined breadth of expertise in small and large molecules, peptides, proteins and monoclonal antibodies enables Kashiv BioSciences to develop products with meaningful clinical differentiation and a compelling value proposition for patients, physicians and payers.